BRIEF REPORT

The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache

SD Silberstein, J Olesen, M-G Bousser, H-C Diener, D Dodick, M First, PJ Goadsby, H Göbel, MJA Lainez, JW Lance, RB Lipton, G Nappi, F Sakai, J Schoenen & TJ Steiner on behalf of the International Headache Society

Introduction

The ICHD-II criteria for 8.2 Medication-overuse headache have been revised based on constructive criticism at the International Headache Research Seminar in Copenhagen in March 2004. The major changes are: (i) elimination of the headache characteristics; and (ii) a new subform (8.2.6 Medication-overuse headache attributed to combination of acute medications) that takes into account patients overusing medications of different classes but not any single class.

The revised section is below.

8. Headache attributed to a substance or its withdrawal

8.2 Medication-overuse headache (MOH)

Previously used terms

Rebound headache, drug-induced headache, medication-misuse headache.

Diagnostic criteria

A Headache1 present on ≥15 days/month fulfilling criteria C and D.

1The headache associated with medication overuse is variable and often has a peculiar pattern with characteristics shifting, even within the same day, from migraine-like to those of tension-type headache.

General comment

Definite or probable? In the particular case of 8.2 Medication-overuse headache, a period of 2 months after cessation of overuse is stipulated in which improvement (resolution of headache, or reversion to its previous pattern) must occur if the diagnosis is to be definite. Prior to cessation, or pending improvement within 2 months after cessation, the diagnosis 8.2.8 Probable medication-overuse headache should be applied. If such improvement does not then occur within 2 months, this diagnosis must be discarded.

8.2 Medication-overuse headache (MOH)

Previously used terms

Rebound headache, drug-induced headache, medication-misuse headache.
B Regular overuse\textsuperscript{2} for >3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache.\textsuperscript{3}

C Headache has developed or markedly worsened during medication overuse.

D Headache resolves or reverts to its previous pattern within 2 months after discontinuation of overused medication.

Comments

MOH is an interaction between a therapeutic agent used excessively and a susceptible patient. The best example is overuse of symptomatic headache drugs causing headache in the headache-prone patient. By far the most common cause of migraine-like headache occurring on ≥15 days per month and of a mixed picture of migraine-like and tension-type-like headaches on ≥15 days per month is overuse of symptomatic antimigraine drugs and/or analgesics. Chronic tension-type headache is less often associated with medication overuse but, especially amongst patients seen in headache centres, episodic tension-type headache has commonly become a chronic headache through overuse of analgesics.

Patients with a pre-existing primary headache who develop a new type of headache or whose migraine or tension-type headache is made markedly worse during medication overuse should be given both the diagnosis of the pre-existing headache and the diagnosis of 8.2 Medication-overuse headache.

The diagnosis of MOH is clinically extremely important because patients rarely respond to preventative medications whilst overusing acute medications.

8.2.1 Ergotamine-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Ergotamine intake on ≥10 days/month on a regular basis for >3 months.

Comment

Bioavailability of ergots is so variable that a minimum dose cannot be defined.

8.2.2 Triptan-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Triptan intake (any formulation) on ≥10 days/month on a regular basis for >3 months.

Comment

Triptan overuse may increase migraine frequency to that of chronic migraine. Evidence suggests that this occurs sooner with triptan overuse than with ergotamine overuse.

8.2.3 Analgesic-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Intake of simple analgesics on ≥15 days/month\textsuperscript{4} on a regular basis for >3 months.

8.2.4 Opioid-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Opioid intake on ≥10 days/month on a regular basis for >3 months.

Comment

Prospective studies indicate that patients overusing opioids have the highest relapse rate after withdrawal treatment.

8.2.5 Combination analgesic-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Intake of combination analgesic medications\textsuperscript{5} on ≥10 days/month on a regular basis for >3 months.

\textsuperscript{2}Overuse is defined in terms of duration and treatment days per week. What is crucial is that treatment occurs both frequently and regularly, i.e. on 2 or more days each week. Bunching of treatment days with long periods without medication intake, practised by some patients, is much less likely to cause medication-overuse headache and does not fulfil criterion B.

\textsuperscript{3}MOH can occur in headache-prone patients when acute headache medications are taken for other indications.

\textsuperscript{4}Expert opinion rather than formal evidence suggests that use on ≥15 days/month rather than ≥10 days/month is needed to induce analgesic-overuse headache.

\textsuperscript{5}Combinations typically implicated are those containing simple analgesics combined with opioids, butalbital and/or caffeine.
8.2.6 Medication-overuse headache attributed to combination of acute medications

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Intake of any combination of ergotamine, triptans, analgesics and/or opioids on ≥10 days/month on a regular basis for >3 months without overuse of any single class alone.

8.2.7 Headache attributed to other medication overuse

Diagnostic criteria

A Headache fulfilling criteria A, C and D for 8.2 Medication-overuse headache.
B Regular overuse for >3 months of a medication other than those described above.

8.2.8 Probable medication-overuse headache

Diagnostic criteria

A Headache fulfilling criteria A and C for 8.2 Medication-overuse headache.
B Medication overuse fulfilling criterion B for any one of the subforms 8.2.1–8.2.7.
C One or other of the following:
   1 Overused medication has not yet been withdrawn.
   2 Medication overuse has ceased within the last 2 months but headache has not so far resolved or reverted to its previous pattern.

Comments

Codable subforms of 8.2.8 Probable medication-overuse headache are 8.2.8.1 Probable ergotamine-overuse headache, 8.2.8.2 Probable triptan-overuse headache, 8.2.8.3 Probable analgesic-overuse headache, 8.2.8.4 Probable opioid-overuse headache, 8.2.8.5 Probable combination analgesic-overuse headache, 8.2.8.6 Headache probably attributed to overuse of acute medication combinations and 8.2.8.7 Headache probably attributed to other medication overuse.

Many patients fulfilling the criteria for 8.2.8 Probable medication-overuse headache also fulfill criteria for either 1.6.5 Probable chronic migraine or 2.4.3 Probable chronic tension-type headache. They should be coded for both until causation is established after withdrawal of the overused medication. Patients with 1.6.5 Probable chronic migraine should additionally be coded for the antecedent migraine subtype (usually 1.1 Migraine without aura).

Copyright

©International Headache Society 2003/4. Applications for copyright permissions should be submitted to Blackwell Publishing, 9600 Garsington Road, Oxford OX4 2DQ, UK (Tel.: +44 1865 776868; fax: +44 1865 714591, website: http://www.blackwellpublishing.com).

Any part of The International Classification of Headache Disorders, 2nd Edition, may be reproduced freely for scientific or clinical uses by institutions, societies or individuals. Otherwise, copyright belongs exclusively to the International Headache Society. Reproduction in any manner for commercial uses requires the Society’s permission which will be granted on payment of a fee. Please contact the publisher at the address above.

Permission for translations must be applied for, and will be granted to National Headache Societies or Linguistic Groups of the International Headache Society. In the absence of a National Headache Society or Linguistic Group, a headache expert may be approved on behalf of the International Headache Society by the Chairman of the Headache Classification Subcommittee to be responsible for translation into a specific language. Sponsorships may be listed and advertisements accepted in translations.

Bibliography


© Blackwell Publishing Ltd Cephalalgia, 2005, 25, 460–465